CY1115282T1 - Ανθρωπινα αντισωματα εναντι του ιου ηπατιτιδας c (hcv) χρησεις αυτων - Google Patents

Ανθρωπινα αντισωματα εναντι του ιου ηπατιτιδας c (hcv) χρησεις αυτων

Info

Publication number
CY1115282T1
CY1115282T1 CY20141100280T CY141100280T CY1115282T1 CY 1115282 T1 CY1115282 T1 CY 1115282T1 CY 20141100280 T CY20141100280 T CY 20141100280T CY 141100280 T CY141100280 T CY 141100280T CY 1115282 T1 CY1115282 T1 CY 1115282T1
Authority
CY
Cyprus
Prior art keywords
human
virus
hcv
human antibodies
antibodies
Prior art date
Application number
CY20141100280T
Other languages
Greek (el)
English (en)
Inventor
Teresa Broering
Susan Sloan
Gregory J Babcock
Donna Ambrosino
William D Thomas Jr
Original Assignee
University Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusetts filed Critical University Of Massachusetts
Publication of CY1115282T1 publication Critical patent/CY1115282T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20141100280T 2007-02-21 2014-04-15 Ανθρωπινα αντισωματα εναντι του ιου ηπατιτιδας c (hcv) χρησεις αυτων CY1115282T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90243207P 2007-02-21 2007-02-21
EP08725537.8A EP2125889B1 (en) 2007-02-21 2008-02-13 Human antibodies against hepatitis c virus (hcv) uses thereof

Publications (1)

Publication Number Publication Date
CY1115282T1 true CY1115282T1 (el) 2017-01-04

Family

ID=39537518

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100280T CY1115282T1 (el) 2007-02-21 2014-04-15 Ανθρωπινα αντισωματα εναντι του ιου ηπατιτιδας c (hcv) χρησεις αυτων

Country Status (21)

Country Link
US (2) US8551484B2 (cg-RX-API-DMAC7.html)
EP (1) EP2125889B1 (cg-RX-API-DMAC7.html)
JP (1) JP5642972B2 (cg-RX-API-DMAC7.html)
KR (1) KR101518081B1 (cg-RX-API-DMAC7.html)
CN (1) CN101679512A (cg-RX-API-DMAC7.html)
AU (1) AU2008223561B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0807929A2 (cg-RX-API-DMAC7.html)
CA (1) CA2678888C (cg-RX-API-DMAC7.html)
CY (1) CY1115282T1 (cg-RX-API-DMAC7.html)
DK (1) DK2125889T3 (cg-RX-API-DMAC7.html)
ES (1) ES2456961T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140316T1 (cg-RX-API-DMAC7.html)
IL (1) IL200432A (cg-RX-API-DMAC7.html)
MX (1) MX2009008706A (cg-RX-API-DMAC7.html)
NZ (1) NZ579706A (cg-RX-API-DMAC7.html)
PL (1) PL2125889T3 (cg-RX-API-DMAC7.html)
PT (1) PT2125889E (cg-RX-API-DMAC7.html)
RS (1) RS53258B (cg-RX-API-DMAC7.html)
SI (1) SI2125889T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008108918A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200905762B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143345A2 (en) * 2008-05-22 2009-11-26 University Of Massachusetts Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN101899419B (zh) 2009-05-25 2013-06-05 中国科学院上海生命科学研究院 昆虫杆状病毒表达系统及用其表达e2蛋白的方法
EP2517556B2 (en) 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2771035B1 (en) * 2011-10-24 2018-04-11 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
PL230663B1 (pl) * 2015-01-15 2018-11-30 Univ Gdanski Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
WO2018200892A1 (en) 2017-04-27 2018-11-01 The Trustees Of The University Of Pennsylvania NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS
CN109738648B (zh) * 2018-12-29 2021-09-17 山东莱博生物科技有限公司 稳定高效表达丙型肝炎病毒核心抗原抗体的工程细胞株及其应用
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
IL295419A (en) 2020-02-11 2022-10-01 Regeneron Pharma Anti-acvr1 antibodies and their uses
JP2024512215A (ja) * 2021-02-12 2024-03-19 メルク・シャープ・アンド・ドーム・エルエルシー メタニューモウイルス、抗原性メタニューモウイルスタンパク質に結合する抗体、及びその使用
CN119462863B (zh) * 2024-12-07 2025-07-22 湖南康润药业股份有限公司 抗hcv核心抗原单克隆抗体、杂交瘤细胞株及应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5308750A (en) 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU663064B2 (en) 1990-10-12 1995-09-28 Abbott Laboratories Hepatitis C virus antibody
DK0569537T3 (da) 1991-01-31 1999-04-06 Abbott Lab Monoklonale antistoffer mod formodede HCV-kapperegioner og fremgangsmåder til anvendelse deraf
FR2677372B1 (fr) 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
JPH06510188A (ja) 1991-08-21 1994-11-17 アボツト・ラボラトリーズ 推定ｈｃｖ　ｎｓ５タンパクに対するモノクローナル抗体およびそれを使用する方法
ZA927837B (en) 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
JP2778886B2 (ja) 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CN1189558C (zh) 1993-10-08 2005-02-16 诺沃奇梅兹有限公司 淀粉酶变体
AU5632296A (en) * 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
ATE423204T1 (de) 1996-11-08 2009-03-15 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
JP2001522599A (ja) 1997-11-06 2001-11-20 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断用及びワクチン用、ｃ型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
CN1325517C (zh) 1998-07-21 2007-07-11 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
US20030180284A1 (en) 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US6692908B1 (en) 1998-11-05 2004-02-17 Stanford University Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
IL137522A (en) 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
AU2002243259B2 (en) 2000-12-01 2008-02-07 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
WO2002060954A1 (en) 2001-01-12 2002-08-08 Karolinska Innovations Ab Materials and methods for treatment of hepatitis c
ITRM20010336A1 (it) 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
AU2003251791B2 (en) 2002-07-03 2009-07-23 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof

Also Published As

Publication number Publication date
SI2125889T1 (sl) 2014-06-30
AU2008223561B2 (en) 2013-10-03
HK1138297A1 (en) 2010-08-20
JP5642972B2 (ja) 2014-12-17
IL200432A0 (en) 2010-04-29
WO2008108918A1 (en) 2008-09-12
HRP20140316T1 (hr) 2014-05-09
JP2010518854A (ja) 2010-06-03
IL200432A (en) 2015-02-26
CA2678888A1 (en) 2008-09-12
KR20100014476A (ko) 2010-02-10
PL2125889T3 (pl) 2014-06-30
RS53258B (sr) 2014-08-29
EP2125889A1 (en) 2009-12-02
KR101518081B1 (ko) 2015-05-06
US20140134175A1 (en) 2014-05-15
ES2456961T3 (es) 2014-04-24
AU2008223561A1 (en) 2008-09-12
US20120288510A1 (en) 2012-11-15
MX2009008706A (es) 2009-09-14
EP2125889B1 (en) 2014-01-15
CA2678888C (en) 2015-04-14
NZ579706A (en) 2012-03-30
PT2125889E (pt) 2014-04-15
US8551484B2 (en) 2013-10-08
CN101679512A (zh) 2010-03-24
DK2125889T3 (da) 2014-04-14
BRPI0807929A2 (pt) 2014-06-24
ZA200905762B (en) 2013-03-27

Similar Documents

Publication Publication Date Title
CY1115282T1 (el) Ανθρωπινα αντισωματα εναντι του ιου ηπατιτιδας c (hcv) χρησεις αυτων
LTPA2021514I1 (cg-RX-API-DMAC7.html)
ATE531731T1 (de) Humane monoklonale antikörper gegen den epidermal-growth-factor-rezeptor (egfr)
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
ATE553131T1 (de) Humane monoklonale antikörper gegen dendritische zellen
ATE342282T1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
DE60037896D1 (de) Menschliche antikörper gegen her2/neu
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MXPA05012571A (es) Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
WO2004045512A3 (en) Human monoclonal antibodies against cd25
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
ATE527278T1 (de) Humane monoklonale antikörper gegen interleukin 8 (il-8)